TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Photocure ASA ( (PHCUF) ) just unveiled an announcement.
Photocure ASA announced that its partner, Asieris Pharmaceuticals, has progressed to the second round of technical review for their photodynamic drug-device product candidate, Cevira. This advancement in the New Drug Application process marks a significant step in the development of Cevira, which aims to offer a non-surgical treatment for high-grade squamous intraepithelial lesions. This progress could enhance Photocure’s industry positioning by potentially expanding its product offerings and impacting stakeholders positively by addressing unmet medical needs.
More about Photocure ASA
Photocure ASA, known as The Bladder Cancer Company, is dedicated to providing innovative solutions for bladder cancer treatment. The company is renowned for its unique technology that enhances cancer cell visibility, improving patient outcomes globally. Headquartered in Oslo, Norway, Photocure is publicly traded on the Oslo Stock Exchange.
YTD Price Performance: 1.94%
Average Trading Volume: 54,881
Current Market Cap: NOK1.71B
See more data about PHCUF stock on TipRanks’ Stock Analysis page.